ChinaBio(R) LLC Week in Review: China Leads Emerging Countries' Pharma M&A

Published: Dec 13, 2012

by Richard Daverman, PhD

December 15, 2012 -- Spending on pharmaceutical M&A deals is up 67% in emerging markets this year, and China, with one-third of the activity, leads the pack; Sinopharm and China Development Bank signed a $6.4 billion agreement to help Sinopharm expand and modernize; Fosun Pharma and Dalian Wanchun Biotech will establish a JV to develop innovative oncology treatments; the Shanghai Institute of Biochemistry and Cell Biology is collaborating with MRC Technology of the UK to develop new drug targets; Jiangxi Boya Bio-Pharma will pay up to $18.5 million to purchase a 68% stake in Zhejiang Haikang Biologicals; DelMar Pharma of Vancouver talked to ChinaBio® Today about its partnership with Guangxi Wuzhou Pharma on a cancer treatment; Mauna Kea Technologies was granted SFDA approval to market its probe-based microscope, Cellvizio®, in China; and Veridex, a Johnson & Johnson company, received SFDA approval for CellSearch, an in vitro diagnostic device that tests for circulating tumor cells in the bloodstream. More details….

Stock Symbols: (SHA: 600196; HK: 2196) (SHA: 300294) (EN: MKEA) (NYSE: JNJ)

Back to news